Hormone menubar
Estrogens - The Female Hormones
GSE
ESTRIOL - The Weak Protective
estrogen
ESTRIOL (E3) - The WEAK, Protective Estrogen - Health Benefits of Topical ESTRIOL Cream
Health Benefits of ESTRIOL
(E3)
ESTRIOL provides a safe form of HRT
ESTRIOL prevents menopausal symptoms.
E.g. hot flashes, without causing
unwanted side effects common to conventional
estrogen replacement therapy.
-
Vaginal dryness, atrophy Lactobacilli depend on the presence of
estrogen.
ESTRIOL
has a binding affinity to vaginal ERs equal to
ESTRADIOL, sufficient to exert a full effect on the vagina after a single dose. For
postmenopausal
vaginal dryness and atrophy, which can lead to vaginitis and cystitis,
ESTRIOL
supplementation is theoretically the most effective and safest
estrogen
choice.
ESTRIOL improves
vaginal flora in
postmenopausal women
Study shows ESTRIOL modifies the vaginal flora and significantly
lowers vaginal pH (from 5.5 to 3.8).
- ESTRIOL recolonized Lactobacilli
(absent prior to therapy) in the vagina after only one month.
In 61% of
postmenopausal women given
ESTRIOL, but in none receiving placebo.
- Additionally, the prevalence of
Enterobacteriaceae colonization fell from 67% to 31%.
No change observed in those receiving placebo.
( Cardozo et al,1998)
Prevent recurrent UTIs in
postmenopausal women
The
intravaginal
ESTRIOL
prevents recurrent UTIs in
postmenopausal women
Intra-vaginally applied
ESTRIOL
cream significantly reduced UTI
incidences in women with recurrent UTIs ESTRIOL
cream (containing 0.5 mg ESTRIOL ,
once daily for two weeks, then twice weekly for
eight months (0.5 versus 5.9 episodes per year). Raz & Stamm, 1993)
ESTRIOL reduces
incontinence in
postmenopausal women The
intravaginal
ESTRIOL
reduced incontinence in
postmenopausal women. In a randomized, placebo-controlled study, 88
women were given 2 mg intravaginal ESTRIOL
suppositories (once daily for two weeks, then
twice weekly for six months) or placebo. Of the women in the
ESTRIOL group,
68% reported improvement in symptoms of incontinence. In addition, measurements
of mean maximal urethral pressure and mean urethral closure pressure were
significantly improved. ( Dessole
et al, 2004)
ESTRIOL (E3)
protective against breast and uterine cancers
ESTRIOL may offer cancer-protective benefits for post menopausal
women without the side effects of
ESTRADIOL
- ESTRIOL's WEAKNESS IS ITS STRENGTH.
ESTRIOL has a much less stimulating effect on the breast
than
ESTRONE and
ESTRADIOL (which is 1000 times more stimulating to breast tissue)
• ESTRIOL
blocks
ESTRONE and
ESTRADIOL
activity.
ESTRIOL binds to
estrogen receptors
(ERs) on the b reast cells, but has much weaker activity. Thus, it actually
blocks the stronger ESTRONE
and
ESTRADIOL
from binding to those cells and subjecting them to the subsequent higher
estrogenic
activity.
• ESTRIOL ▲
correlates with cancer▼.
In the 1966 Journal of the American Medical Association H.M. Lemmon, M.D.
reported a study showing that higher levels of
ESTRIOL in the body correlate with remission of breast cancer. Dr. Lemmon
demonstrated that women with
ESTRIOL excretion. He also
observed that women without ESTRIOL levels,
compared to ESTRONE
and ESTRADIOL levels, than women
with
- Vegetarian and Asian women
have high levels of
ESTRIOL
(presumed to be the result of a high intake of phytoestrogenic soy)
and these women are at much lower risk of breast cancer
than other women
- ESTRIOL
has a much less stimulating effect on uterine
lining than ESTRADIOL
• Receptor binding studies have indicated that
ESTRIOL has
a binding affinity to endometrial estrogen receptors only about 10% of
ESTRADIOL. After a single dose (as
opposed to a continuously supplied dose) of ESTRIOL, the
binding to the endometrial estrogen receptor is too short to induce
proliferation
ESTRIOL arrests
breast cancerUnlike the stronger estrogens
ESTRADIOL
or
estrone ,
ESTRIOL has not been shown to stimulate the
uterus or breast cells either. In either animal studies or human clinical trials.
A clinical trial of
2.5 to 5 mg per day ESTRIOL
therapy in 28 premenopausal and postmenopausal breast cancer patients
demonstrated that estriol
induced remission or arrest of metastatic tumors in six (37%)
of the women .
ESTRIOL improves
skinEstrogens are needed for producing the proteins collagen and
elastin. These give skin its elasticity and
structure, and also hyaluronic acid, responsible for holding moisture in the
skin.
- Collagen is lost at
a rate of ~30% in first 5 years after menopause. Then ~ 2.1%/year over 20 years.
- Mid/Late 1990's studies
demonstrated that ESTRIOL
face cream is very effective at reversing wrinkles and
other skin aging problems occurring at menopause
- You need a "Goldilocks" Dose" of
ESTRIOL.
i.e. it must be just right, because estrogen levels too high or too low give lower collagen levels.
Estrogen
replacement therapy significantly increases dermal skin thickness.
Determined by various studies.
- Estrogen
therapy in castrated mice increased GAG content by 70% in 2 weeks.
In women, increases in GAGs
lead to skin thickness increases that are much higher than from collagen content
increases alone;
Estriol may support the
cardiovascular system
Some menopausal women taking oral
ESTRIOL experienced
a significant decrease in both systolic and diastolic blood pressure. These women took 2 mg/day oral ESTRIOL for 12 months.
(Takahashi et al, 2000)
Some elderly women taking
ESTRIOL decreased
their total cholesterol and triglycerides and increased their levels of
beneficial HDL cholesterol. The study evaluated 20 postmenopausal and 29 elderly women taking an oral
Estriol dose of 2 mg/day for 10 months.
(Nishibe et al, 1996)
Estriol improves bone
mineral status in women with osteoporosisJapanese study of 75 postmenopausal women supplementing
ESTRIOL
showed increases in bone mineral density, a decrease in menopausal symptoms, and
no increased risk of endometrial hyperplasia (tissue
overgrowth that may precede cancer). After 50 weeks of taking 2 mg/day of ORAL
estriol cyclically
and 800 mg/day of calcium lactate. (Minaguchi et al,
1996)
Another study found that supplementing
estriol in addition to calcium lactate
significantly increased bone mineral density compared to calcium supplement
alone. Postmenopausal
and elderly women
took 2
mg/day of ORAL estriol and 1,000 mg/day of
calcium lactate versus 1,000 mg/day calcium lactate alone.
(Nishibe et al, 1996)
References Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L.
(1998) Meta-analysis of estrogen therapy in the management of urogenital atrophy in
postmenopausal women: second report of the hormone and urogenital therapy
committee. Obstet Gynecol ;92:722-7.
Dessole S, Rubattu G, Ambrosini G et al (2004 Jan) Efficacy of
low-dose intravaginal estriol on urogenital aging in postmenopausal women.
Menopause. ;11(1):49-56.
Minaguchi H, Uemura T, Shirasu K, et al (1996 Jun) Effect of estriol
on bone loss in postmenopausal Japanese women: a multicenter prospective open
study. J Obstet Gynaecol Res.;22(3):259-65.
Nishibe A, Morimoto S, Hirota K, et al (1996 May) Effect of estriol
and bone mineral density of lumbar vertebrae in elderly and postmenopausal
women. Nippon Ronen Igakkai Zasshi. 33(5):353-9.
Raz R, Stamm WE (1993) A controlled trial of intravaginal estriol
in postmenopausal women with recurrent urinary tract infections.N Engl J Med ;329:753-7.
Takahashi K, Okada M, Ozaki T, et al (2000 May) Safety and efficacy of
oestriol for symptoms of natural or surgically induced menopause. Hum Reprod.; 15(5):1028-36.
